Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients

References

• Allahyari A, Hashemi SM, Nazemian F, et al. The relationship between risk factors and survival in adult acute lymphoblastic leukemia. Iran J Cancer Prev. 2016;9(4):e50. doi: 10.17795/ijcp-5045
   Web of Science ®Google Scholar
• Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–1666. doi: 10.1016/j.mayocp.2016.09.010
   PubMed Web of Science ®Google Scholar
• Al Ustwani O, Gupta N, Bakhribah H, et al. Clinical updates in adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 2016;99:189–199. doi: 10.1016/j.critrevonc.2015.12.007
   PubMed Web of Science ®Google Scholar
• Wright GJ, Jones M, Puklavec MJ, et al. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology. 2001;102(2):173–179. doi: 10.1046/j.1365-2567.2001.01163.x
   PubMed Web of Science ®Google Scholar
• Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23(6):285–290. doi: 10.1016/S1471-4906(02)02223-8
   PubMed Web of Science ®Google Scholar
• Walker DG, Lue LF. Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains? Future Neurol. 2013;8(3):321–332. doi: 10.2217/fnl.13.14
   Google Scholar
• Gorczynski RM. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages. Eur J Immunol. 2001;31(8):2331–2337. doi: 10.1002/1521-4141(200108)31:8<2331::AID-IMMU2331>3.0.CO;2-#
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Chen Z, Lee L, et al. Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol. 2002;104(3):256–264. doi: 10.1006/clim.2002.5232
   PubMed Web of Science ®Google Scholar
• Pankratova S, Bjornsdottir H, Christensen C, et al. Immunomodulator CD200 promotes neurotrophic activity by interacting with and activating the fibroblast growth factor receptor. Mol Neurobiol. 2016;53(1):584–594. doi: 10.1007/s12035-014-9037-6
   PubMed Web of Science ®Google Scholar
• Jenmalm MC, Cherwinski H, Bowman EP, et al. Regulation of myeloid cell function through the CD200 receptor. J Immunol. 2006;176(1):191–199. doi: 10.4049/jimmunol.176.1.191
   PubMed Web of Science ®Google Scholar
• Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290(5497):1768–1771. doi: 10.1126/science.290.5497.1768
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation. 2005;79(4):488–491.
   PubMed Web of Science ®Google Scholar
• Coles SJ, Wang EC, Man S, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011;25(5):792–799. doi: 10.1038/leu.2011.1
   PubMed Web of Science ®Google Scholar
• Farag SS, VanDeusen JB, Fehniger TA, et al. Biology and clinical impact of human natural killer cells. Int J Hematol. 2003;78(1):7–17. doi: 10.1007/BF02983234
   PubMed Web of Science ®Google Scholar
• Dalmazzo LF, Jacomo RH, Marinato AF, et al. The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. Br J Haematol. 2009;144(2):223–229. doi: 10.1111/j.1365-2141.2008.07457.x
   PubMed Web of Science ®Google Scholar
• Shibuya A, Nagayoshi K, Nakamura K, et al. Lymphokinerequirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1995;85(12):3538–3546.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Estrov Z, et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002;26(7):643–649. doi: 10.1016/S0145-2126(01)00188-6
   PubMed Web of Science ®Google Scholar
• Montero I, Rios E, Parody R, et al. CD56 in T-cell acute lymphoblastic leukaemia: a malignant transformation of an early myeloid-lymphoid progenitor? Haematologica. 2003;88(9):E127–E128.
   Google Scholar
• Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:2222–2230. doi: 10.1200/JCO.1997.15.6.2222
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–918. doi: 10.1200/JCO.2008.18.6916
   PubMed Web of Science ®Google Scholar
• Chessells JM, Bailey CC, Richards S. MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. The Medical Research Council Working Party on childhood leukaemia. Leukemia. 1992;6(Suppl. 2):157–161.
   PubMedGoogle Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Long-term follow-up results of hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer J. 2004;101(12–15):2788–2801. doi: 10.1002/cncr.20668
   Google Scholar
• Porwit A, Rajab A. Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features. Int J Lab Hematol. 2015;37(Suppl 1):133–143. doi: 10.1111/ijlh.12368
   PubMedGoogle Scholar
• Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact ofCD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93–100. doi: 10.1309/AJCP59UORCYZEVQO
   PubMed Web of Science ®Google Scholar
• Adnan Awad S, Kamel MM, Ayoub MA, et al. Immunophenotypic characterization of cytogenetic subgroups in Egyptian pediatric patients with B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl.):S19–S24.e1. doi: 10.1016/j.clml.2016.02.032
   PubMedGoogle Scholar
• Tembhare PR, Ghogale S, Ghatwai N, et al. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000. Cytometry B Clin Cytom. 2016;96:2691. doi:10.1002/cyto.b.21486. [Epub ahead of print].
   Google Scholar
• Fischer L, Gokbuget N, Schwartz S, et al. CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica. 2009;94(2):224–229. doi: 10.3324/haematol.13543
   PubMed Web of Science ®Google Scholar
• Abdulateef NA, Ismail MM, Aljedani H. Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. Asian Pac J Cancer Prev. 2014;15(1):221–227. doi: 10.7314/APJCP.2014.15.1.221
   PubMedGoogle Scholar
• Paietta E, Neuberg D, Richards S, et al. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol. 2001;66(3):189–196. doi: 10.1002/1096-8652(200103)66:3<189::AID-AJH1043>3.0.CO;2-A
   PubMed Web of Science ®Google Scholar
• Seegmiller AC, Kroft SH, Karandikar NJ, et al. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132(6):940–949. doi: 10.1309/AJCP8G5RMTWUEMUU
   PubMed Web of Science ®Google Scholar
• Hussein S, Gill KZ, Sireci AN, et al. Aberrant T-cell antigen expression in B lymphoblastic leukaemia. Br J Haematol. 2011;155(4):449–456. doi: 10.1111/j.1365-2141.2011.08870.x
   PubMed Web of Science ®Google Scholar
• Damiani D, Tiribelli M, Raspadori D, et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget. 2015;6(30):30212–30221. doi: 10.18632/oncotarget.4901
   PubMed Web of Science ®Google Scholar
• Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161–1164. doi: 10.1038/sj.leu.2402174
   PubMed Web of Science ®Google Scholar
• Murakami J, Shimizu Y. Hepatic manifestations in hematological disorders. Int J Hepatol. 2013;2013:1–13, Article ID 484903, 13 pages. doi: 10.1155/2013/484903
   Google Scholar
• Yoshikawai T, Tanizawa A, Suzuki K, et al. The usefulness of T1-weighted magnetic resonance images for diagnosis of acute leukemia manifesting musculoskeletal symptoms prior to appearance of peripheral blood abnormalities. Case Rep Pediatr. 2016:2016. Article ID 2802596, 6 pages. doi: 10.1155/2016/2802596
   Google Scholar
• Cox CV, Diamanti P, Hazell M, et al. CD200 may be a potential target for therapy in standard risk childhood ALL. Blood. 2014;124(21):4787–4478.
   Web of Science ®Google Scholar
• Salami K, Alkayed K, Halalsheh H, et al. Hemopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome positive acute lymphoblastic leukemia. Hemat Oncol Stem Cell Ther. 2013;6(1):34–41. doi: 10.1016/j.hemonc.2013.03.001
   PubMedGoogle Scholar
• Crist W, Carroll A, Shuster J, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood. 1990;76(3):489–494.
   PubMed Web of Science ®Google Scholar
• Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566–568. doi: 10.1038/sj.leu.2404559
   PubMed Web of Science ®Google Scholar
• Maio Y, Fani L, Wu Y, et al. Low expression of CD200 predicts shorter time to tratment in chronic lymphocytic lrukrmia. Oncotarget. 2016;7(12):13551–13562.
   PubMed Web of Science ®Google Scholar
• Li L, Tian Y, Shi C, et al. Over-expression of CD200 predicts poor prognosis in cutaneous squamous cell carcinoma. Med Sci Monit. 2016;22:1079–1084. doi: 10.12659/MSM.895245
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Wang X, Lo EH. CD200 increases alternatively activated macrophages through cAMP-response element binding protein – C/EBP-beta signaling. J Neurochem. 2016;136(5):900–906. doi: 10.1111/jnc.13492
   PubMed Web of Science ®Google Scholar
• Suzuki R, Murata M, Kami M, et al. Prognostic significance of CD7(+)CD56(+) phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003;77(5):482–489. doi: 10.1007/BF02986617
   PubMed Web of Science ®Google Scholar
• Hu W, Wang X, Yang R, et al. Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults. Hematology. 2016;22:1–7.
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178:5595–5605. doi: 10.4049/jimmunol.178.9.5595
   PubMed Web of Science ®Google Scholar
• Zocchi MR, Vidal M, Poggi A. Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells. Exp Cell Res. 1993;204(1):130–135. doi: 10.1006/excr.1993.1017
   PubMed Web of Science ®Google Scholar